Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Report Ocean is delighted to unveil an exhaustive analysis of the Philippines Diabetes Devices Market, presenting a detailed exploration of its various dimensions from 2018 to 2032. Our in-depth study ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

“Insulin used to cost around $500 for one box, and now it’s down to somewhere around $150, $200, so they’ve really dropped ...

Jabil acquires Pharmaceutics International to enhance commercial prospects in the emerging market of CDMO services.

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Read and watch stories from teachers, students and the school community as they share their experiences transitioning into a New Year of Learning. Learn about how your child can access Free Kinder, ...